Clin2
NCT07202598Possibly a fitRecruiting

Testing emapalumab for gut inflammation in APECED

Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy Enteritis

Treatments studied

Part of Hormones & metabolism, Immune system & allergy clinical trials.

This trial tests a drug called emapalumab to treat chronic gut inflammation (enteritis) in people with APECED, a rare immune disorder. It aims to see if the drug can help when other treatments haven't worked.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
30 people
Ages
2 years to 75 years
Study type
Interventional

Who can take part

  • You are between 2 and 75 years old.
  • You have APECED (confirmed by genetic testing or a doctor) and chronic gut inflammation that has lasted more than 6 months.
  • You are already in another NIH study (protocol 11-I-0187) about fungal infections.
  • You have not tried other treatments for gut inflammation, or those treatments did not help.
  • You are willing to take antiviral medicines (like acyclovir) to prevent herpes virus reactivation.
  • You are willing to use effective birth control if you or your partner could become pregnant.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT01386437Recruiting
Study immune problems and fungal infections

This study looks at how immune system problems relate to fungal infections, using medical records and lab tests on blood and tissue. It may help researchers understand the cause of these infections—especially for people with inherited immune conditions—and improve future care.

Bethesda, Maryland
NCT07744919Not yet recruiting· Phase 2
Treating severe liver inflammation with emapalumab

This trial tests whether the drug emapalumab can help children with severe liver inflammation that has not improved with steroids. It aims to reduce liver damage and improve recovery.

Atlanta, Georgia
NCT07609810Not yet recruiting
Palmitoylethanolamide treatment for difficult-to-control ulcerative colitis

This trial tests whether a natural compound called palmitoylethanolamide can help ulcerative colitis patients whose symptoms aren't controlled by standard medications. You'd be taking this alongside your current treatments to see if it reduces inflammation and symptoms.

Cairo, El-Abbasia
NCT07583641Recruiting· Phase 2
Testing Efgartigimod for Autoimmune Brain Inflammation

This trial tests a medicine called efgartigimod to treat autoimmune encephalitis (AIE)—a rare condition where the immune system attacks the brain. The study enrolls children 12+ and adults to see if this drug can reduce symptoms and help recovery.

Tucson, Arizona
NCT06285825Recruiting· Phase 2
Study of emapalumab for low blood counts after CAR T-cell therapy

This study tests a drug called emapalumab to help people whose blood counts stay low for weeks after CAR T-cell therapy for certain types of lymphoma. The goal is to see if the drug can help the body recover normal blood cell production.

Houston, Texas
NCT06487000Not yet recruiting· Phase 2
Testing EC-18 for moderate to severe eczema

This trial tests an experimental drug called EC-18 (a pill) for people with moderate to severe eczema that hasn't been controlled well with creams. It aims to see if different doses of the drug can safely reduce itching and skin rash.

Hear when a new Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy Enteritis trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.